SELLAS Life Sciences Group, Inc. - 8-K Filing

SELLAS Life Sciences reports positive topline Phase 3 REGAL trial results for galinpepimut-S (GPS) in AML patients, meeting primary overall survival endpoint. (Items: 7.01 Regulation FD Disclosure On November 17, 2026, SELLAS Life Sciences Group, Inc, 8.01 Other Events)

SEC EDGAR ·

Tickers: $SLS

Read the full article at SEC EDGAR

More Regulatory news